virtual-cell
(3)
Omphalos Lifesciences Inc
Omphalos Lifesciences is a Dallas-based biotech software company building a programmable virtual cell platform. Founded by computational biologist Daehwan Kim - creator of the widely used HISAT and TopHat sequencing tools - the company created L++, a high-level programming language that lets biologists describe, simulate, and visualize living systems the way software engineers write code. Its Life Designer platform aims to accelerate drug discovery, precision medicine, and biomanufacturing by running experiments in silico before they hit the lab bench.
Syntensor
Syntensor builds frontier AI foundation models for cellular biology and human genetics that simulate how drugs act inside the body before a single patient is dosed. Using dynamical systems simulation and neural differential equations over multi-omics data, its platform predicts drug efficacy, systemic toxicity, and the causes of clinical trial failure, then explains the mechanism behind each prediction. Founded out of the University of Cambridge and now headquartered in San Francisco, the company aims to build an accurate, interpretable mechanistic model of human physiology that de-risks pharmaceutical R&D.
Noetik
Noetik is an AI-native biotechnology company building foundation models of human cancer biology to discover precision immunotherapies. It pairs one of the world's largest proprietary spatial-omics datasets - hundreds of millions of spatially resolved tumor and immune cells - with a high-throughput in vivo CRISPR Perturb-Map platform to train multimodal virtual cell models like OCTO-VC. These models simulate gene expression, cell states, and tumor-immune interactions, letting researchers find drug targets and predict patient response computationally. Founded in 2022 by former Recursion leaders Ron Alfa and Jacob Rinaldi, Noetik has raised roughly $62M and licenses its models to pharma, including an anchor partnership with GSK.